GT BIOPHARMA INC (GTBP)

Company Profile

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in Brisbane California, California and currently employs 2 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of novel immuno-oncology products based on its Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. TriKE platform generates therapeutics designed to harness and enhance the cancer killing abilities of a patients own natural killer cells (NK) cells. GTB-3550 is its TriKE product candidate which is a single-chain, tri-specific recombinant fusion protein construct composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. The GTB-3550 Phase 1 clinical trial for treatment of patients with CD33-expression. The company is also using its TriKE platform to develop therapeutics useful for the treatment of infectious disease, such as for the treatment of patients infected by the human immunodeficiency virus.

Company Info

GT BIOPHARMA INC

8000 Marina Blvd, Suite 100

Brisbane California CALIFORNIA 90212

P: 18003049888

CEO: Anthony J. Cataldo

Employees: 2

Website: https://www.gtbiopharma.com/